TOP1 and small cell lung carcinoma: However, the antitumor effect exerted by the combination of ATR inhibitor with topoisomerase (TOP1) inhibitor and the subsequent mechanisms underlying enhanced tumor immunogenicity in SCLC remain poorly understood.